Navigation Links
Woman's Recovery From Advanced Melanoma Could Help Guide Research
Date:3/7/2012

WEDNESDAY, March 7 (HealthDay News) -- Combining the immune-based drug ipilimumab with targeted radiation therapy improved one advanced melanoma patient's ability to fight the deadly skin cancer, a new study says.

The treatment triggered a strong immune response, which resulted in shrinkage of both the tumor treated with radiation as well as tumors located at distant locations in the body, according to the study, published in the March 8 issue of the New England Journal of Medicine.

The patient was followed for seven years, from her initial diagnosis of melanoma in 2004, through a series of treatments, to her eventual disease regression in April 2011.

According to health experts, this is a rare documented case of an immune response called the "abscopal effect" that can occur in cancer treatment.

Although the results were dramatic in this patient, one expert said such cases are isolated.

"Although this patient represents a successful outcome, it does not mean that this treatment approach will be as effective in other patients," said Dr. Craig Devoe, oncologist at the Monter Cancer Center, part of the North Shore-Long Island Jewish Health System, in Lake Success, N.Y. He was not involved in the study.

In this case, the patient had a preexisting immune response to an antigen called NY-ESO-1. This immune response occurs in certain cancer patients and they are more likely to respond to ipilimumab than others, explained the scientists at the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center in New York City.

"The use of radiation therapy modulated the patient's immune system, resulting in an increased antibody response to one portion of the NY-ESO-1 protein, as well as increased antibody responses to other antigens," research leader Dr. Jedd Wolchok said in a Ludwig Institute news release. Wolchok is associate attending physician and director of Immunotherapy Clinical Trials at Memorial Sloan-Kettering, and director of the Ludwig Institute/Cancer Research Institute Cancer Vaccine Collaborative.

At the same time that the therapy was evoking this strong immune-system response, "the radiation lowered the level of a population of [immunosuppressive] cells, allowing the immune system to function more robustly, leading to better recognition and control of the disease," Wolchok said.

This case report illustrates the power of harnessing the human immune system to fight cancer, the researchers said.

"The immune system differs in each of us," Wolchok said. "In studying one person's response, we were able to carefully investigate the clinical findings with in-depth laboratory studies, which suggested that a change in the immune system was vital to the successful results."

This case has sparked interest in clinical trials to test this treatment approach for melanoma and prostate cancer, the research team said.

Devoe agreed that the woman's successful treatment may offer intriguing new avenues of research.

"Dr. Wolchok and his team are outstanding researchers in the field of melanoma," Devoe said. "The immune system has been and continues to be one of the most important aspects of melanoma treatment."

Devoe believes the case of this one patient "does increase the evidence that the NY-ESO-1 protein is a very important immune system target and further study of this particular phenomenon is needed."

More information

The American Cancer Society has more about melanoma.

-- Robert Preidt

SOURCES: Craig Devoe, M.D., oncologist, Monter Cancer Center, North Shore-LIJ Health System, Lake Success, NY; Ludwig Institute for Cancer Research, news release, March 7, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug Seems to Speed Recovery After Traumatic Brain Injury
2. Being Fit Before Stroke May Aid Recovery
3. High levels of tau protein linked to poor recovery after brain injury
4. Recovery From Concussions in Young Athletes May Take Longer Than Thought
5. Painkiller Dependence Before Knee Surgery May Slow Recovery
6. Brain function involved in recovery of facial paralysis is different according to sex
7. Helping others helps teens stay on the road to addiction recovery
8. Dementia May Impede Stroke Recovery
9. Blood-pressure-lowering drug after stroke aids recovery, study finds
10. Commonly used supplement may improve recovery from spinal cord injuries
11. Common stimulant may speed recovery from general anesthesia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Woman's Recovery From Advanced Melanoma Could Help Guide Research
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name ... New York, NY, on December 3rd, to benefit Holy Name Medical Center's programs ... event, which raised over $1 million - the largest event in the Center's ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, ... Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related to ... prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 with ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has ... report to their offering. ... The global travel vaccines market to grow at ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the sales of various ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
Breaking Medicine Technology: